Private Equity 24 Hours

Last updated: June 15, 2026, 5:30 PM ET

AI‑Focused Credit and Deal Activity

Apollo and Blackstone closed a $35bn private‑credit syndication to fund Anthropic’s next‑generation AI chips, underscoring growing lender appetite for deep‑tech infrastructure. The same week, Morgan Stanley exited Brazos Delaware II for $1.6bn, achieving an 8x EBITDA multiple based on projected 2027 earnings and highlighting the premium investors still assign to high‑growth private‑equity assets. Meanwhile, Abry sealed a $780m continuation fund for Centauri Health, allowing the firm to retain a top‑line healthcare platform as secondary markets tighten.

Strategic Acquisitions and Portfolio Builds

Nuvei completed a $2.75bn take‑private of Payoneer, expanding its cross‑border payments footprint and positioning the combined entity to capture rising ecommerce volumes. In Europe, L Catterton pursued a stake in fitness brand Hyrox, targeting the fast‑growing extreme‑training segment that has attracted $200m of venture capital this year. Across the Atlantic, H.I.G. Capital sold CRO Celerion for $1.8bn, delivering a sizable exit for a contract‑research specialist as pharma firms accelerate clinical pipelines.

Secondary Market Growth and Debt Financing

Argosy doubled its fund size with a $145m raise, reflecting heightened demand for small‑deal secondary exposure amid limited primary opportunities. In the credit arena, Blue Owl led a €355m credit vehicle for Veld Capital, earmarked for follow‑on investments that leverage an already robust deal pipeline. Separately, Birkenstock prepared a €900m bond issuance to fund shareholder buybacks, marking the German footwear maker’s first bond sale in over five years and signaling confidence in its cash‑flow generation.

Leadership Moves and Portfolio Realignments

CalPERS appointed a new head of alternatives, steering its $250bn alts mandate toward greater alignment with ILPA standards and a focus on evergreen structures. In the UK, Sycamore Partners lost a suitor after Sigma Healthcare withdrew from the Boots sale, narrowing the competitive field for the pharmacy chain’s privatization. Finally, Partners Group co‑founder Urs Wietlisbach split the family office into a separate unit, a succession‑driven restructuring that may unlock additional capital for bespoke private‑equity investments.